VivoSeq
Other

Hyperammonemia

5

Pipeline Programs↗

0

Active Trials↗

3

Companies Involved↗

Hyperammonemia is an early-stage landscape with 5 programs across 3 companies. The most active players are TenNor Therapeutics (Suzhou) Limited, Salix, Liminal BioSciences Ltd.. 1 program is in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

27/100

Pipeline Velocity

0/100

Mech. Concentration

100/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

T

TenNor Therapeutics (Suzhou) Limited

1 program

Phase 2S

Salix

1 program

PreclinicalL

Liminal BioSciences Ltd.

1 program

Preclinical

Pipeline

Programs by Phase

Analysis

Trial Status

4

clinical trials

Completed3 · 75%
Unknown status1 · 25%

Clinical Trials

Trial Activity

N-Carbamylglutamate (Carbaglu) In The Treatment Of Hyperammonemia
Unknown status·—·Phase 2/3·NCT00843921·52 enrolled
Short-Term Outcome of N-Carbamylglutamate in the Treatment of Acute Hyperammonemia
Completed·—·Phase 2·NCT01599286·35 enrolled
Efficacy and Safety of Sodium Benzoate in the Management of Hyperammonemia in Infants, Children and Adolescent With Chronic Liver Disease.
Completed·IInstitute of Liver and Biliary Sciences, India·N/A·NCT04022941·108 enrolled
PK Profile and Preliminary Efficacy of TNP-2092 Capsules in Liver Cirrhosis Patients With Hyperammonemia
Completed·TTenNor Therapeutics (Suzhou) Limited·Phase 1/2·NCT06135675·36 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)